Previous 10 | Next 10 |
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-02-14 16:43:55 ET More on Arm Holdings, BioMarin Pharmaceutical, etc. Howmet Aerospace Inc. 2023 Q4 - Results - Earnings Call Presentation Howmet Aerospace Inc. (HWM) Q4 2023 Earnings Call Transcript Arm Holdings Stock: Valuation Too High For Its Growth Rate ...
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced...
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress PR Newswire New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostati...
2024-01-30 14:30:03 ET Piper Sandler analyst issues UNDERPERFORM recommendation for BMRN on January 30, 2024 02:00PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $89.795 at issue of the analyst recommendation. The overall analyst consensu...
2024-01-21 09:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities rose in ...
2024-01-19 14:33:49 ET Summary BioMarin Pharmaceutical is a biotech company that focuses on delivering enzyme products for rare genetic disorders. The company has launched two new products, Voxzogo for Achondroplasia and Valoctocogene Roxaparvovec (Roctavian) for severe hemophilia...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA PR Newswire SAN RAFAEL, Calif. , Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announ...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...